ARMP logo

Armata Pharmaceuticals, Inc. Stock Price

NYSEAM:ARMP Community·US$372.9m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

ARMP Share Price Performance

US$10.55
9.30 (744.00%)
US$10.55
9.30 (744.00%)
Price US$10.55

ARMP Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate risk with weak fundamentals.

5 Risks
0 Rewards

Armata Pharmaceuticals, Inc. Key Details

US$4.9m

Revenue

US$15.7m

Cost of Revenue

-US$10.8m

Gross Profit

US$163.0m

Other Expenses

-US$173.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-4.74
-220.49%
-3,544.03%
-117.5%
View Full Analysis

About ARMP

Founded
n/a
Employees
60
CEO
Deborah Birx
WebsiteView website
www.armatapharma.com

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.

Recent ARMP News & Updates

Recent updates

No updates